The benefit of nivolumab was seen in stage 3 disease (HR: 0.65, 0.52–0.83), with a strong trend toward improvement in resected stage 4 patients (HR: 0.70, 0.45–1.10).
1
—
—
The benefit of nivolumab was seen in stage 3 disease (HR: 0.65, 0.52–0.83), with a strong trend toward improvement in resected stage 4 patients (HR: 0.70, 0.45–1.10).